Erasca
ERAS
13.61
-0.61
-4.29%
Erasca
US · ERAS
#2103 by market cap
Listed 2021
13.61
-0.61
-4.29%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions increased by 15 in the most recent period (2026/Q3).
- Total institutional ownership fell 1.5 percentage points.
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 89.41% -1.52pp
- Institutions
- 309 +15
- As of
- 2026/Q3 vs. prior period
Holder types
Mutual Fund41.86%
Hedge Fund22.47%
VC/PE Fund20.59%
Individual/Insider9.65%
Public Company2.47%
Private Company0.76%
Sovereign Wealth Fund0.60%
Insurance Company0.43%
Government Pension Fund0.21%
Other0.96%
Top holders as of 2026-06-30
Jonathan Lim
9.25% · 32.36M sh
T. Rowe Price Group, Inc.
7.85% · 27.46M sh
Frazier Life Sciences Management, LP
7.14% · 24.98M sh
BlackRock
6.79% · 23.74M sh
RTW Investments, LP
5.13% · 17.95M sh
VR Management, LLC
5.12% · 17.89M sh
Vanguard Capital Management, LLC
3.98% · 13.91M sh
State Street Global Advisors
3.95% · 13.82M sh
Artal Group S.A.
3.77% · 13.20M sh
Logos Global Management, L.P.
3.47% · 12.15M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 38 buys · 12 sells
| Name | Role | Stake |
|---|---|---|
| Jonathan Lim | Chairperson & CEO | 9.25% |
| Alexander Casdin | Independent Director | 0.19% |
| David Chacko | CFO & Chief Business Officer | 0.08% |
| James Bristol | Lead Independent Director | 0.06% |
| Pratik Multani | Independent Director | 0.05% |
| Ebun Garner | Chief Legal Officer | 0.01% |
| Valerie Harding-Start | Independent Director | 0.01% |
| Julie Hambleton | Independent Director | 0.00% |
| Jean I. Liu | Independent Director | -- |
| Michael Varney | Chairman of Research & Development, Scientific Advisory Board Member and Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-09 | Charles Fuchs | President of Research & Development | Other Derivative Acquisition | +1,300,000 | $18.12 |
| 2026-06-25 | Jean I. Liu | Independent Director | Other Derivative Acquisition | +29,888 | $16.01 |
| 2026-06-25 | Alexander Casdin | Independent Director | Other Derivative Acquisition | +29,888 | $16.01 |
| 2026-06-25 | Pratik Multani | Independent Director | Other Derivative Acquisition | +29,888 | $16.01 |
| 2026-06-25 | James Bristol | Lead Independent Director | Other Derivative Acquisition | +29,888 | $16.01 |
| 2026-06-25 | Julie Hambleton | Independent Director | Other Derivative Acquisition | +29,888 | $16.01 |
| 2026-06-25 | Valerie Harding-Start | Independent Director | Other Derivative Acquisition | +29,888 | $16.01 |
| 2026-03-31 | Ebun Garner | Chief Legal Officer | Derivative Exercise and Sale | -80,000 | $1.70–16.40 |
| 2026-03-03 | Shannon Morris | Chief Medical Officer | Derivative Exercise and Sale | -20,000 | $1.70–15.04 |
| 2026-01-28 | Michael Varney | Chairman of Research & Development, Scientific Advisory Board Member and Director | Other Derivative Acquisition | +96,000 | $10.31 |
| 2026-01-28 | Jonathan Lim | Chairperson & CEO | Other Derivative Acquisition | +2,000,000 | $10.31 |
| 2026-01-28 | Ebun Garner | Chief Legal Officer | Other Derivative Acquisition | +560,000 | $10.31 |
| 2026-01-28 | Shannon Morris | Chief Medical Officer | Other Derivative Acquisition | +625,000 | $10.31 |
| 2026-01-28 | David Chacko | CFO & Chief Business Officer | Other Derivative Acquisition | +640,000 | $10.31 |
| 2026-01-06 | Ebun Garner | Chief Legal Officer | Derivative Exercise and Sale | -120,000 | $1.70–5.59 |
| 2025-12-31 | Jean I. Liu | Independent Director | Other Derivative Acquisition | +20,617 | $3.72 |
| 2025-12-31 | Alexander Casdin | Independent Director | Other Derivative Acquisition | +23,872 | $3.72 |
| 2025-12-31 | Pratik Multani | Independent Director | Other Derivative Acquisition | +19,532 | $3.72 |
| 2025-12-31 | James Bristol | Lead Independent Director | Other Derivative Acquisition | +37,762 | $3.72 |
| 2025-12-31 | Valerie Harding-Start | Independent Director | Other Derivative Acquisition | +24,306 | $3.72 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:30:00 · For reference only, not investment advice and not tailored to your situation.
Erasca discussion 0 comments